 Metabolic syndrome affects more than one in five adults and is characterized by atherogenic dyslipidemia, elevated blood pressure, and elevated plasma glucose. Paroxysm proliferator-activated receptors, PPARs, transcriptional factors that may serve as potential therapeutic targets for treating metabolic syndrome and its related risk factors. PPAR and PPAR regulate lipid metabolism, insulin sensitivity, and glucose homeostasis, while PPAR regulates lipid metabolism, glucose homeostasis, anti-inflammation, and fatty acid oxidation. The therapeutic potential of PPAR modulators in the treatment of thrombosis is being explored. This article was authored by Francisco A. Monesolve, Rada D. Pirasani, Fernando Delgado Lopez, and others.